Kala Bio (KALA) Assets Average (2017 - 2026)
Kala Bio (KALA) posted Assets Average of $10.9 million for Q1 2026, down 36.81% sequentially from $17.3 million in Q4 2025, and down 78.98% YoY from $51.9 million in Q1 2025.
Kala Bio (KALA) Assets Average (2017 - 2026) Analysis & Trends
Kala Bio has reported Assets Average for 10 years, with the latest figure at $10.9 million in Q1 2026.
- Quarterly Assets Average fell 78.98% year-over-year to $10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (down 78.98% YoY) and the FY2025 annual result came in at $32.5 million, down 41.69% from the prior year.
- Assets Average slipped to $10.9 million in Q1 2026 per KALA's latest filing, from $17.3 million in the prior quarter.
- Over five years, Assets Average peaked at $125.5 million in Q1 2022 and troughed at $10.9 million in Q1 2026.
- A 5-year average of $61.4 million and a median of $57.8 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2025 and 2026: Assets Average slipped 4.81% in 2025, then plunged 78.98% in 2026.
- Over 5 years, Assets Average stood at $86.3 million in 2022, then sank by 32.14% to $58.5 million in 2023, then fell by 6.41% to $54.8 million in 2024, then tumbled by 68.5% to $17.3 million in 2025, then sank by 36.81% to $10.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $10.9 million, $17.3 million, and $30.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | 10.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.90 Mn |
| Dec 31, 2025 | 17.26 Mn |
| Sep 30, 2025 | 30.54 Mn |
| Jun 30, 2025 | 42.15 Mn |
| Mar 31, 2025 | 51.87 Mn |
| Dec 31, 2024 | 54.78 Mn |
| Sep 30, 2024 | 57.84 Mn |
| Jun 30, 2024 | 57.32 Mn |
| Mar 31, 2024 | 54.49 Mn |
| Dec 31, 2023 | 58.53 Mn |
| Sep 30, 2023 | 63.81 Mn |
| Jun 30, 2023 | 69.36 Mn |
| Mar 31, 2023 | 79.52 Mn |
| Dec 31, 2022 | 86.26 Mn |
| Sep 30, 2022 | 85.34 Mn |
| Jun 30, 2022 | 98.28 Mn |
| Mar 31, 2022 | 125.50 Mn |
| Dec 31, 2021 | 166.62 Mn |
| Sep 30, 2021 | 204.64 Mn |
| Jun 30, 2021 | 222.65 Mn |